GlassScriptPhysician profile
Muhammad Ahmad
NPI 1467832691
$3,044.92
in general payments reported to CMS, 2019-2025
23 companies · $872 in 2025
The $872 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $38.85 · 2021: $285 · 2022: $307 · 2023: $493 · 2024: $702 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $681.33 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $346.45 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $342.26 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $301.84 | 2021-2025 | |
| Glaxosmithkline, LLC. | $252.71 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $237.87 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Seqirus USA INC | $132.72 | 2023-2025 | Fluad, Flucelvax, Flucelvax Quadrivalent |
| Pfizer INC. | $128.60 | 2019-2025 | |
| Abbott Laboratories | $110.31 | 2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $73.80 | 2023-2024 | |
| Abbvie INC. | $54.24 | 2023-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.47 | 2021-2022 | |
| Exact Sciences Corporation | $50.65 | 2024 | Cologuard Collection Kit |
| Dexcom, INC. | $48.92 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $32.46 | 2025 | Korlym |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $31.91 | 2025 | Rezdiffra |
| Lucid Diagnostics INC. | $31.90 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $25.88 | 2025 | Eliquis |
| Boston Scientific Corporation | $24.98 | 2025 | Watchman Access System |
| Ardelyx, INC. | $24.57 | 2024 | Ibsrela |
| Axsome Therapeutics, INC. | $24.53 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $18.80 | 2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.